[6-K] Evogene Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Evogene Ltd. furnished its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six-month period ended June 30, 2025. The filing lists interactive data files for consolidated interim statements of financial position, profit or loss, changes in equity, cash flows and notes. Exhibits 99.1 and 99.2 are incorporated by reference into the company’s registration statements on Form F-3 and Form S-8 and will form part of those filings to the extent not later superseded. The Form 6-K is signed by the CFO and serves to furnish interim financial reporting and management commentary for the first half of 2025.

Positive

• Unaudited consolidated financial statements for the six months ended June 30, 2025 were furnished
• Operating and Financial Review and Prospects included, offering management commentary for H1 2025
• Interactive data files for interim statements and notes were provided, aiding analyst review
• Exhibits 99.1 and 99.2 were incorporated by reference into Form F-3 and Form S-8 registration statements

Negative

• Filing text contains no financial figures here, so performance metrics are unavailable without Exhibit 99.1
• Unaudited status means figures are preliminary and not audited
• No forward-looking guidance or summary performance context is included in this cover text

Insights

Financial Reporting Specialist

Interim financials and OFR were furnished for H1 2025.

The company provided unaudited condensed consolidated financial statements and an Operating and Financial Review covering the six months ended June 30, 2025, plus interactive data files for standard interim statements and notes. This fulfills routine disclosure expectations for a foreign private issuer and supports transparency for periodic performance assessment.

Key dependencies include the actual figures in Exhibit 99.1 and narrative detail in Exhibit 99.2; without those documents here, analysts must review the exhibits to assess profitability, cash flow, and liquidity trends for H1 2025.

Capital Markets Analyst

Furnishing interim statements may affect investor access to updated H1 2025 metrics.

Incorporation of Exhibits 99.1 and 99.2 into Form F-3 and S-8 registration statements ensures these interim disclosures become part of the company’s offering and employee plan registration records. That administrative step preserves regulatory linkage between current financials and securities registration materials.

Near-term attention should focus on the actual interim metrics and any changes disclosed in the OFR; those figures will determine whether the market views this filing as materially positive or negative for valuation over the coming reporting cycle.

0001574565falseQ2--12-31

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street

Park Rehovot, Rehovot

7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Results of Operations- Six Months Ended June 30, 2025

This Report of Foreign Private Issuer on Form 6-K, or Form 6-K, is being furnished by Evogene Ltd., or Evogene, to the Securities and Exchange Commission, or SEC, for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, unaudited condensed consolidated financial statements of Evogene as of and for the six-month period ended June 30, 2025; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Evogene’s Operating and Financial Review and Prospects, which discusses and analyzes Evogene’s financial condition and results of operations as of, and for the six-month period ended, June 30, 2025.

 

The contents of Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2025.
99.2	Operating and Financial Review and Prospects for the six-month period ended June 30, 2025.
101	Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Interim Statements of Financial Position, (ii) Consolidated Interim Statements of Profit or Loss, (iii) Consolidated Interim Statements of Changes in Equity; (iv) Consolidated Interim Statements of Cash Flows, and (v) Notes to Interim Consolidated Financial Statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
 
Date: September 30, 2025 EVOGENE LTD.
(Registrant)
 
By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer

FAQ

What did Evogene (EVGN) file in this Form 6-K?

The company furnished unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six months ended June 30, 2025, plus interactive data files.

Are the financial statements audited?

No. The filing lists unaudited condensed consolidated financial statements for the period.

Which exhibits were included and how are they used?

Exhibits 99.1 (financial statements) and 99.2 (OFR) were furnished and are incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.

Does this Form 6-K include interactive data?

Yes. Interactive data files are listed for interim statements of financial position, profit or loss, changes in equity, cash flows, and accompanying notes.

Who signed the Form 6-K?

The Form 6-K is signed by Yaron Eldad, Chief Financial Officer.